1260811-97-9

Usage

Uses

Used in Pharmaceutical Development:
7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine is used as a lead compound in the pharmaceutical industry for the development of new drugs. Its unique structure and the presence of the trifluoromethyl group may enhance its binding affinity to specific biological targets, making it a valuable candidate for the treatment of various diseases.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine serves as a research tool to study the interactions between chemical compounds and biological systems. Its properties can be further explored to understand its potential therapeutic effects and to optimize its structure for better efficacy and safety.
Used in Chemical Industry:
The trifluoromethyl group in 7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine may impart specific chemical and physical properties that are useful in various chemical processes and applications. 7-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine can be utilized in the synthesis of other complex molecules or as an intermediate in the production of specialty chemicals.

Upstream product

• 81565-18-6 2-chloro-4-trifluoromethyl pyridine 

Relevant academic research and scientific papers

Oxidative cyclization of 1-(pyridin-2-yl)guanidine derivatives: A synthesis of [1,2,4]triazolo[1,5-a]pyridin-2-amines and an unexpected synthesis of [1,2,4]triazolo[4,3-a]pyridin-3-amines

Oxidative cyclization of 1-(pyridin-2-yl)guanidine derivatives using N-chlorosuccinimide and aqueous potassium carbonate has been investigated. Chlorination of 1-(5-nitropyridin-2-yl)guanidine by N-chlorosuccinimide in methanol followed by addition of aqueous potassium carbonate gave rise to cyclization and afforded 6-nitro-[1,2,4]triazolo[1,5-a]pyridin-2-amine in one-pot. In the course of studying the scope and limitation of the reaction, it was found that some of the examined 1-(pyridin-2-yl)guanidine derivatives gave not only the desired [1,2,4]triazolo[1,5-a]pyridin-2-amines but also unexpected [1,2,4]triazolo[4,3-a]pyridin-3-amine products. As plausible reaction mechanisms of this oxidative cyclization, diazirine formation and nitrene formation are presented.

GAMMA SECRETASE MODULATERS

The invention relates to compounds of formula ( I ) wherein R1/R1' are independently from each other hydrogen, halogen, lower alkoxy or cyano; R2 is lower alkyl, halogen, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by OR, =0, -C(O)O-lower alkyl, -C(O)NH-lower alkyl, cyano, CH2-O-lower alkyl, cycloalkyl, NRR'or is -O-(CH2)o-phenyl optionally substituted by halogen, or is -(CH2)o-phenyl optionally substituted by one, two or three substituents, selected from halogen, -(CH2)o-cyano, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, C(O)H, -CH2-NH2-, -CH2-NH-C(O)O-lower alkyl, -CH2-NH-C(O)-lower alkyl, -CH2-NH-lower alkyl, -CH2-NH-S(O)2-lower alkyl, lower alkoxy or by lower alkoxy substituted by halogen, or is -(CH2)o-cycloalkyl, or is -(CH2)o-heterocycloalkyl which is optionally substituted by halogen, CF3, lower alkyl, -CH2CN, -C(O)-lower alkyl, -C(O)O-lower alkyl or S(O)2-lower alkyl, or is heteroaryl selected from the group consisting of furanyl, pyrazinyl, pyridinyl, benzooxazolyl or benzoimidazolyl which are optionally substituted by lower alkyl, or is 4-methyl-3,4-dihydro-2H-benzo[l,4]oxazine R and R' are independently from each other hydrogen or lower alkyl, and o is 0 or 1; R3 may occur once or twice and is lower alkyl; A is Formula a), b), c), d), e), f), h), i), j) and Formula k); R2' is hydrogen, lower alkyl, lower alkyl substituted by halogen, C(O)-lower alkyl, S(O)2-lower alkyl or phenyl optionally substituted by halogen; hetaryl is a 5 or 6 membered N, S or O-containing heteroaryl group; n is O, 1, 2 or 3; if n is 2 or 3, R2 may be the same or not; or to pharmaceutically active acid addition salts thereof. The present compounds of formula ( I ) are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi- infarct dementia, dementia pugilistica and Down syndrome.

GAMMA SECRETASE MODULATORS

The invention relates to compounds of formula wherein R1, R1′, R2, R3, n, A, and hetaryl are defined herein or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.